Predicting the Long-Term Risk of Type 2 Diabetes and Cardiovascular Disease With Orforglipron in People With Overweight or Obesity: A Post Hoc Analysis of the ATTAIN-1 Trial.
- DOI
- 10.1111/dom.71322
- Published
- 2026-09-17
- Container
- Diabetes Obes Metab
- Publisher
- Not recorded
- Open access
- no
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1111/dom.71322,
title = {Predicting the Long-Term Risk of Type 2 Diabetes and Cardiovascular Disease With Orforglipron in People With Overweight or Obesity: A Post Hoc Analysis of the ATTAIN-1 Trial.},
author = {Shinde S and Kahles F and Vasileva-Metodiev S and Griffin R and Liu-Seifert H and Lebrec J and Xavier NA and Li R and Klise SR and Singh A and Aberle J.},
year = {2026},
journal = {Diabetes Obes Metab},
doi = {10.1111/dom.71322},
url = {https://doi.org/10.1111/dom.71322}
}RIS
TY - JOUR TI - Predicting the Long-Term Risk of Type 2 Diabetes and Cardiovascular Disease With Orforglipron in People With Overweight or Obesity: A Post Hoc Analysis of the ATTAIN-1 Trial. AU - Shinde S AU - Kahles F AU - Vasileva-Metodiev S AU - Griffin R AU - Liu-Seifert H AU - Lebrec J AU - Xavier NA AU - Li R AU - Klise SR AU - Singh A AU - Aberle J. PY - 2026 JO - Diabetes Obes Metab DO - 10.1111/dom.71322 UR - https://doi.org/10.1111/dom.71322 ER -
APA
S, S., F, K., S, V., R, G., H, L., J, L., NA, X., R, L., SR, K., A, S., & J., A. (2026). Predicting the Long-Term Risk of Type 2 Diabetes and Cardiovascular Disease With Orforglipron in People With Overweight or Obesity: A Post Hoc Analysis of the ATTAIN-1 Trial.. Diabetes Obes Metab. https://doi.org/10.1111/dom.71322
Source records
- europe-pmc · retrieved 2026-09-26T03:15:46.132Z